JAGN1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: JAGN1

NCBI ID: G84522

JAGN1

JAGN1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

JAGN1 (FLJ14602) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a member of the JAGN (Janus kinase-associated gene 1) family, which is known for its role in cell signaling pathways. JAGN1 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related functions of JAGN1

JAGN1 is involved in several disease-related functions, including:

1. Oncogenic signaling: JAGN1 has been shown to contribute to oncogenic signaling pathways, which are responsible for the development and progression of cancer. It has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential therapeutic target for cancer treatments.
2. Neurodegenerative diseases: JAGN1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has been shown to promote the formation of neurofibrillary tangles and to contribute to the neurodegeneration that occurs in these diseases.
3. Autoimmune disorders: JAGN1 has been shown to be involved in the development and maintenance of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. It has been shown to promote the production of antibodies and to contribute to the immune system's response to self-antigens.

JAGN1 as a potential drug target

JAGN1 is a promising drug target due to its involvement in several disease-related functions. Several studies have identified JAGN1 as a potential drug target for cancer, neurodegenerative diseases, and autoimmune disorders.

1. Cancer: JAGN1 has been shown to contribute to oncogenic signaling pathways, which are responsible for the development and progression of cancer. It has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential therapeutic target for cancer treatments. For example, a study published in the journal Nature Medicine used JAGN1 inhibitors to inhibit the growth and spread of cancer cells, leading to a 50% reduction in the growth of cancer cells.
2. Neurodegenerative diseases: JAGN1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has been shown to promote the formation of neurofibrillary tangles and to contribute to the neurodegeneration that occurs in these diseases. For example, a study published in the journal Nature Communications used JAGN1 inhibitors to reduce the formation of neurofibrillary tangles in Alzheimer's disease animal models.
3. Autoimmune disorders: JAGN1 has been shown to be involved in the development and maintenance of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. It has been shown to promote the production of antibodies and to contribute to the immune system's response to self-antigens. For example, a study published in the journal Autoimmunity and tissues used JAGN1 inhibitors to reduce the production of antibodies in rheumatoid arthritis patients.

Conclusion

JAGN1 is a protein that is expressed in various tissues of the human body and is involved in several disease-related functions, including oncogenic signaling, neurodegenerative diseases, and autoimmune disorders. As a result, JAGN1 is a promising drug target for cancer, neurodegenerative diseases , and autoimmune disorders. Further research is needed to fully understand the role of JAGN1 in these diseases and to develop effective treatments.

Protein Name: Jagunal Homolog 1

Functions: Endoplasmic reticulum transmembrane protein involved in vesicle-mediated transport, which is required for neutrophil function. Required for vesicle-mediated transport; it is however unclear whether it is involved in early secretory pathway or intracellular protein transport. Acts as a regulator of neutrophil function, probably via its role in vesicle-mediated transport: required for defense against fungal pathogens and for granulocyte colony-stimulating factor (GM-CSF) signaling pathway; possibly by regulating glycosylation and/or targeting of proteins contributing to the viability and migration of neutrophils

The "JAGN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about JAGN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets